YCC-6 Xenograft Model Service for Gastric Cancer

YCC-6 Xenograft Model Service for Gastric Cancer provides a robust preclinical platform for evaluating novel therapeutic candidates against metastatic gastric adenocarcinoma. At Alfa Cytology, we specialize in developing and characterizing validated xenograft models using the YCC-6 cell line to accelerate your oncology drug discovery and biomarker development programs with reliable, reproducible data.

Overview of YCC-6 Xenograft Model for Gastric Cancer

The YCC-6 xenograft model is established from the YCC-6 human gastric adenocarcinoma cell line, originally derived from malignant ascites of a Korean patient at the Yonsei Cancer Center. This cell line represents a metastatic phenotype with a doubling time of approximately 48 hours and exhibits epithelial morphology consistent with poorly cohesive gastric carcinoma. The YCC-6 model carries a documented MET mutation (p.Arg1382Ter, c.4144C>T) and has been extensively profiled through whole exome sequencing, transcriptomic microarray, and RNA sequencing, making it particularly relevant for studies targeting receptor tyrosine kinase pathways and c-MET inhibitor development.

In vivo, YCC-6 cells demonstrate reliable tumorigenicity in immunodeficient mouse strains, forming subcutaneous tumors that recapitulate key histological and molecular features of the parental cell line. The model has been utilized in preclinical studies to evaluate angiogenic factor expression, chemotherapeutic sensitivity, and gene therapy approaches. Its well-characterized genomic background and consistent growth kinetics make the YCC-6 xenograft a valuable tool for pharmacogenomic research and translational studies in gastric cancer drug development.

Figure 1. Landscape of genetic alterations in BRD family genes and related genes in 49 GC cell lines in relation to iBET-151 sensitivity. (Kang, Sun Kyoung, et al., 2021)

Cell Line Information: YCC-6

The YCC-6 cell line is a well-established human gastric adenocarcinoma line with comprehensive molecular and phenotypic characterization. The following table summarizes the essential cell line information relevant to xenograft model development:

Our Services

Alfa Cytology leverages the extensively characterized YCC-6 cell line to deliver high-quality gastric cancer xenograft models tailored to your preclinical research needs. Our integrated service platform encompasses model establishment, in vivo pharmacology, biomarker analysis, and comprehensive histopathological evaluation, ensuring that every study generates actionable, publication-ready data to advance your therapeutic pipeline.

Workflow of YCC-6 Xenograft Model Construction

The construction of the YCC-6 xenograft model follows a standardized, quality-controlled workflow designed to ensure tumor engraftment consistency, animal welfare compliance, and data reproducibility across batches. Each stage is monitored with defined endpoints and documented for traceability.

1. Cell Line Authentication and Expansion: YCC-6 cells are authenticated by STR profiling and confirmed mycoplasma-free before expansion. Cells are cultured under optimized conditions to maintain logarithmic growth and harvested at 80-90% confluence for inoculation.
2. Animal Preparation and Ethical Approval: Immunodeficient mice (e.g., NOD-SCID or nude mice) are acclimatized under pathogen-free conditions. All procedures are conducted under approved IACUC protocols with humane endpoints predefined.
3. Tumor Cell Inoculation: A suspension of 1-5 x 10^6 YCC-6 cells in serum-free medium mixed with Matrigel is injected subcutaneously into the flank of each mouse. Alternatively, orthotopic implantation into the gastric wall may be performed for site-specific studies.
4. Tumor Monitoring and Caliper Measurement: Tumor growth is monitored twice weekly using digital calipers. Tumor volume is calculated via the modified ellipsoid formula (length x width^2 x 0.5). Mice are randomized into treatment groups once tumors reach 100-150 mm3.
5. Treatment Administration and Endpoint Collection: Test compounds are administered according to the study design (IV, IP, or PO). Body weight and clinical signs are recorded daily. At endpoint, tumors are excised, weighed, and processed for downstream histology, IHC, and molecular analysis.
6. Histopathological and Molecular Analysis: Excised tumors undergo formalin fixation, paraffin embedding, and sectioning for H&E and target-specific IHC (e.g., Ki-67, c-MET, CD31). Tissue aliquots are snap-frozen for RNA/DNA extraction and pharmacodynamic biomarker assessment.

Figure 2. YCC-6 xenograft model construction workflow.

Case Study-YCC-6 Xenograft Model Development

In a representative preclinical engagement, the YCC-6 xenograft model was successfully established with consistent tumor take rates and growth kinetics suitable for efficacy evaluation. Following model validation, a pilot therapeutic study was conducted to assess tumor response to a candidate anti-cancer agent, with parallel pharmacodynamic biomarker profiling. The study demonstrated measurable tumor growth inhibition correlated with target engagement, providing preliminary proof-of-concept data. Full dataset and statistical analysis are available upon request to support your internal decision-making and IND-enabling studies.

Why Choose Alfa Cytology?

Alfa Cytology combines rigorous scientific execution with flexible project management to deliver xenograft models that meet the highest standards of preclinical oncology research. Our YCC-6 gastric cancer model service is designed to generate robust, reproducible data while accelerating your compound development timeline.

• Extensively authenticated YCC-6 cell line with documented MET mutation and genomic profiling ensures biologically relevant model fidelity.
• Standardized xenograft workflow with defined QC checkpoints guarantees batch-to-batch consistency and reproducible tumor growth kinetics.
• Comprehensive in vivo pharmacology capabilities including tumor monitoring, body weight tracking, and survival analysis with IACUC-compliant protocols.
• Integrated histopathology and biomarker analysis services (IHC, IF, RNA/DNA extraction) available within the same project workflow.
• Dedicated study directors provide real-time data updates, customized dosing schedules, and adaptive endpoint strategies tailored to your compound mechanism.
• Rapid project initiation with established cell banking and qualified vendor relationships to minimize lead times for urgent screening campaigns.

Contact Us

Ready to advance your gastric cancer therapeutic program with the YCC-6 xenograft model? Contact us today to discuss your study objectives, timeline, and specific assay requirements. Our team of experienced oncology scientists is prepared to design a customized preclinical strategy that aligns with your development goals and delivers high-quality, decision-enabling data. Reach out to us now and let Alfa Cytology be your trusted partner in preclinical cancer research. Please reach out to us today via our inquiry form or email to learn more about our YCC-6 Xenograft Model services.

For research use only. Not intended for any clinical use.